June 14, 2019
Geo-political events are weighing upon this market and its participants
News: The battle for the sickle cell disease therapy, bluebird bio (BLUE) and Global Blood Therapeutics (GBT) <read more> issue updates
Pre-open indications: 4 BUYs and 1 SELL
Insight from what's likely to remain a volatile climate
May 20, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes?
Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019?
Why spend time finding sector news and analytics … it’s all right here!
June 15, 2019
Thursday’s gold became Friday’s tin
Saturday news: Editas Medicine (EDIT closed -$0.78 or -3.47%) announced results from a follow-up study to assess two different CRISPR genome editing strategies, one targeting the BCL11A erythroid enhancer (BC11Ae) and one targeting the beta-globin locus, for the treatment of sickle cell disease and beta-thalassemia. EDIT reported the data at the 24th Congress of the European Hematology Association in Amsterdam.
Pre-open indications: 2 HITs and 3 MISS (2 by pennies)
No sigh of relief in volatility
May 20, 2019
Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here!
May 19, 2019
A scorecard of earnings of 45 covered companies 41 so far: 2 acquired (AST, OSIR) 1 on acquisition hold - ONCE) and 1 set to be reversed (HSGX) ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"
March 31, 2019
A scorecard of (AKA) earnings of 45 covered companies 44 out of 45 ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
June 15, 2019
RegMed Investors’ (RMi) closing bell: alchemy in reverse
June 14, 2019
RegMed Investors’ (RMi) pre-open: investors consider time horizons, traders say forget the near and long-term
June 13, 2019
RegMed Investors’ (RMi) closing bell: upward motion
June 13, 2019
RegMed Investors’ (RMi) pre-open: new money, non; old money, leaving; trading money, da!
June 12, 2019
RegMed Investors’ (RMi) closing bell: a return from the bottom
June 12, 2019
RegMed Investors’ (RMi) pre-open: gap up, gap down, what will fill the gaps?
June 11, 2019
RegMed Investors’ (RMi) closing bell: risk has never stopped being a four letter expletive
June 11, 2019
RegMed Investors’ (RMi) pre-open: trading dollars at work, not new investor monies
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
